Is discontinuation of clopidogrel necessary for intracapsular hip fracture surgery? Analysis of 102 hemiarthroplasties by Fahad S. Hossain et al.
ORIGINAL ARTICLE
Is discontinuation of clopidogrel necessary for intracapsular hip
fracture surgery? Analysis of 102 hemiarthroplasties
Fahad S. Hossain • Rohit Rambani •
Helen Ribee • Lutz Koch
Received: 18 July 2012 / Accepted: 9 March 2013 / Published online: 6 April 2013
 The Author(s) 2013. This article is published with open access at Springerlink.com
Abstract
Background An increasing number of elderly patients are
managed with long-term antiplatelet therapy. Such patients
often present with hip fracture requiring surgical interven-
tion and may be at increased risk of perioperative bleeding
and complications. The aim of this study was to ascertain
whether it is necessary to stop clopidogrel preoperatively to
avoid postoperative complications following hip hemiar-
throplasty surgery in patients with intracapsular hip fracture.
Materials and methods A retrospective review of 102
patients with intracapsular hip fracture with either periop-
erative clopidogrel therapy [clopidogrel group (CG)] or no
previous clopidogrel exposure [no clopidogrel group
(NCG)] who underwent hip hemiarthroplasty surgery was
undertaken. Statistical comparison on pre- and postopera-
tive haemoglobin, American Society of Anesthesiologists
(ASA) grade, comorbidities, operative time, transfusion
requirements, hospital length of stay (LOS), wound infec-
tion, haematoma and reoperation rate between the two
groups was undertaken. Regression analysis was under-
taken to ascertain the risk ratios (RR) of complications and
transfusion associated with clopidogrel.
Results There was no difference with respect to ASA
grade, comorbidities (except cardiac comorbidities), pre-
and postoperative haemoglobin levels, operation time, age
or gender between the two groups. Four and two patients,
respectively, required transfusion postoperatively in the CG
and NCG (p = 0.37). There was no difference with respect
to LOS, wound infection, haematoma or reoperation rate
between the two groups postoperatively. The covariate-
adjusted RR for complications and transfusion while being
on clopidogrel were 0.43 [95 % confidence interval (CI)
0.07–2.60] and 3.96 (95 % CI 0.40–39.68), respectively.
Conclusion Continuing clopidogrel therapy throughout
the perioperative period in patients with intracapsular hip
fracture is not associated with an increased risk of com-
plications following hip hemiarthroplasty surgery.
Keywords Clopidogrel  Hip fracture  Transfusion 
Complications
Introduction
Mortality associated with fragility hip fractures is high,
with more than a third of patients dying within 12 months
[1]. Most of these deaths are due to medical causes related
to concurrent comorbidities [2]. Over 65 % of hip fracture
patients have an American Society of Anesthesiologists
(ASA) score of 3 or above, further reflecting the high
prevalence of coexisting comorbidities [3], of which
ischaemic heart disease is common. In fact, previous cohort
studies have suggested a genetic link between a diagnosis
of cardiovascular disease and subsequent development of
fragility hip fractures [4, 5]. It is therefore not surprising
that a significant proportion of these elderly patients will be
on antiplatelet therapy at presentation with a hip fracture.
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Clopidogrel irreversibly inhibits platelet aggregation
which continues throughout the lifespan of the platelets
affected [6]. It is superior to aspirin in secondary pre-
vention of ischaemic stroke, myocardial infarction or
vascular death [7], with dual therapy using clopidogrel and
aspirin being most effective in the management of vascular
events particularly in patients following coronary stenting
[8, 9]. While the therapeutic advantages of clopidogrel
therapy are evident, its continuation during the perioper-
ative phase has its disadvantages. With regards to cardiac
surgery specifically, continued clopidogrel therapy has
resulted in increased perioperative blood loss, haemor-
rhagic complications, transfusion requirement and infec-
tion [10, 11]. The potential risk of haematoma associated
with regional anaesthesia techniques [12] in orthopaedic
patients, reinforces the rationale for disruption in anti-
platelet therapy with ensuing delay in surgery. Concerns
with hip fracture patients on concomitant clopidogrel
therapy have often led to its discontinuation with
subsequent delay prior to definitive surgical treatment.
Previous studies have shown that up to 21 % of ortho-
paedic surgeons and more than 40 % of orthopaedic
departments in the UK follow a policy of preoperative
interruption in clopidogrel therapy for 5–10 days in hip
fracture patients [13, 14].
In contrast, however, discontinuation of clopidogrel
therapy perioperatively may result in considerable thera-
peutic and surgery-related disadvantages. Acute with-
drawal of clopidogrel results in a prothrombotic and
proinflammatory state that may complicate surgery,
resulting in adverse clinical events [15]. Furthermore,
cessation of clopidogrel therapy for at least 5 days is
required to allow return of platelet function adequate for
implementation of regional anaesthesia in hip fracture
surgery [16]. This in itself is of major concern, as surgical
delay in hip fracture management of more than 2 days is
associated with a significantly increased risk of complica-
tions and mortality within 30 days and 1 year [17, 18].
From a cardiac perspective, discontinuation of clopidogrel
is associated with an increased incidence of myocardial
infarction or mortality in patients treated either medically
or with coronary stenting for acute coronary syndrome. In
both groups over half the events occurred within 90 days of
stopping clopidogrel therapy [19].
There is a paucity of information on the risks of
continuing clopidogrel perioperatively in hip fracture
surgery with a lack of consensus on this issue amongst
surgeons [13]. We therefore aimed to ascertain whether
there were any differences in blood transfusion, wound
complications and reoperations during the postoperative
period between patients who continued their long-term
clopidogrel therapy throughout the perioperative period
and those who were not on clopidogrel.
Materials and methods
Patients were retrospectively identified from an audit
database of hip fractures at our institution between April
2008 and April 2010 with verification of clopidogrel
exposure from electronic discharge summaries detailing
medication history. Informed consent was obtained prior to
patient inclusion in our study. The study was planned and
implemented in accordance with the ethical standards of
the Helsinki Declaration as amended in 2000 and was
approved by our institution’s clinical governance commit-
tee. We included all patients over the age of 50 years with
a displaced intracapsular fracture treated surgically within
48 h of admission. We excluded patients with extra-
capsular fractures, polytrauma, pathological fractures,
coagulopathies, haematological malignancies, pre-existing
warfarin or dipyridamole therapy, thrombocytopaenia on
admission (platelet count \150 9 109/L), recent active
bleeding or gastrointestinal ulcers.
Case notes were reviewed to collect data on age, gender,
ASA grade, presence of individual comorbidities and pre-
operative haemoglobin (Hb) levels in all patients. We also
collected surgery-related data including operation duration
and use of cement. Our outcome measures included post-
operative Hb levels, transfusion rates, incidence of wound
infection, symptomatic haematomas, reoperations for any
cause and hospital length of stay (LOS). We reviewed
patient anaesthetic charts to determine the type of anaes-
thesia that was given (i.e. general or regional anaesthesia)
and furthermore if there were any ensuing anaesthetic
complications.
We identified consecutive patients who were surgically
treated while long-term clopidogrel therapy was continued
[intervention group (CG)] and consecutive patients without
any history of clopidogrel exposure [control group (NCG)].
Patients in both groups may or may not have been on
additional aspirin therapy.
Preoperative medical optimisation prior to surgery was
undertaken via multidisciplinary consultations. Patients in
both groups were treated with hip hemiarthroplasty using a
lateral approach. Our cemented prostheses of choice were
either the Furlong cemented hemiarthroplasty (JRI,
Sheffield, UK) or the Thompson hemiarthroplasty (Depuy,
Leeds, UK). Our uncemented prosthesis of choice was the
hydroxyapatite-coated Furlong H-A.C hemiarthroplasty
(JRI, Sheffield, UK). The Austin–Moore hemiarthroplasty
(Depuy, Leeds, UK) was reserved for older patients with
poor pre-injury mobility and higher perioperative risks.
Antibiotic prophylaxis was undertaken with 1 g of intra-
venous flucloxacillin (or vancomycin in cases of penicillin
allergy) at anaesthetic induction and two further postop-
erative doses. All patients received thromboprophylaxis
with 40 mg of enoxaparin postoperatively for 6 weeks
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administered subcutaneously. A multidisciplinary approach
to postoperative care with input from orthogeriatricians,
physiotherapists and occupational therapists were under-
taken prior to discharge of patients to their own home or a
community rehabilitation facility. They were encouraged
to ambulate immediately as pain allowed postoperatively.
All patients were subjected to a repeat pelvis radiograph
and blood tests at 48 h postoperatively.
All categorical variables were analysed using the chi-
squared or Fisher’s exact test, while the independent-sam-
ples Students t/Mann–Whitney test was used for continuous
variables when comparing the two groups in univariate
analysis. We combined all complications of haematoma,
wound infection or reoperation for any reason into a binary
variable (1 = any complication occurred, 0 = no compli-
cation occurred). In so doing we did not account for the
severity of the complications. Any other approach which
would have accounted for severity of complications would
make continuing clopidogrel appear more protective against
complications, hence introducing bias in favour of its con-
tinuation. The need for transfusion was also measured as a
binary variable (1 = transfusion needed, 0 = transfusion
not needed). We compared the outcomes of these binary
variables of complication and transfusion using a working
Poisson regression model adjusting for covariates. We
chose parameters which had a significance level of p \ 0.15
on initial univariate analysis as covariates [20]. The use of
the working Poisson model allows direct estimation of
relative risk, which is easier to interpret and more relevant
clinically [21, 22]. It is hence preferred over logistic
regression, which estimates odds ratios and has been used
for relative risk estimation in previous cohort studies [23].
Results
There were 50 and 52 patients in the CG and NCG,
respectively. The demographic and comorbidity-related
data are summarised in Table 1, while data pertaining to
surgery-related factors and outcome variables are summa-
rised in Tables 2 and 3, respectively. The mean ages in the
CG and NCG were 82.8 ± 7.3 years and 83.2 ± 7.8 years,
respectively (p = 0.82). There was no statistically signifi-
cant difference with respect to gender (p = 0.87) or ASA
grade (p = 0.085) between the two groups. The mean
preoperative Hb levels were 12.5 ± 1.4 and 12.6 ± 1.2
g/dL, respectively, in the CG and NCG (p = 0.72). There
was no statistically significant difference in comorbidities
between the two groups except that of cardiovascular dis-
ease (p \ 0.0001) which was higher in the CG compared
with the NCG. Similarly there was no statistically signifi-
cant difference in the proportion of patients on concomitant
aspirin between the two groups (p = 0.14) (Table 1).
There were 7 and 15 patients who had an Austin–Moore
prosthesis implanted in the CG and NCG, respectively.
There was a higher proportion of cemented procedures in
the CG compared with the NCG (p = 0.01). However,
there was no statistically significant difference with respect
to operation duration between the two groups (p = 0.072).
Similarly there was no statistically significant difference in
mean hospital LOS between the two groups (p = 0.28)
(Table 2).
The mean postoperative Hb levels were 10.8 ± 1.5 and
11.1 ± 1.5 g/dL in the CG and NCG (p = 0.37). Four
patients in the CG required a transfusion as compared with
two patients in the NCG. A total of 8 blood units were
utilised in the CG while 5 in the NCG. The mean number
of units used was 2 ± 0 and 2.5 ± 0.71 in the CG and
NCG, respectively (p = 0.16). The covariate-adjusted rel-
ative risk (RR) of having a blood transfusion while
continuing clopidogrel was 3.96 (95 % CI 0.40–39.68).
There were three cases of symptomatic haematomas in
the CG with one in the NCG (p = 0.36). The overall
wound infection rate for both groups was 2.94 %, with one
and two patients developing wound infections in the CG
and NCG, respectively (p = 1.0). One patient in the CG
had a reoperation for evacuation of a haematoma. In the
NCG, one patient had a reoperation for a deep wound
infection, while another returned to the operating room for
reduction of a dislocated hip. The RR for all complications
combined while continuing clopidogrel after adjusting for
covariates was 0.43 (95 % CI 0.07–2.60) (Table 3).
General anaesthesia was more common in the CG with
88 % of patients receiving a general anaesthetic, while
65.4 % of patients in the NCG received regional anaesthesia
(Table 2). There were no anaesthetic-related complications
in either group.
Discussion
Fragility hip fractures are common in patients with multi-
ple comorbidities including that of cardiovascular disease.
Our cohort study demonstrates that continued clopidogrel
antiplatelet therapy during the perioperative period in such
patients does not result in worse outcomes as compared
with a perioperative period in intracapsular hip fracture
patients who have never been exposed to clopidogrel. The
overall transfusion and complication rates were low with
no statistically significant difference between the two
groups.
Coronary dilatation for cardiovascular disease is com-
mon, accounting for over 2 million cases annually in
Western countries [24], of which the majority are percu-
taneous stenting procedures with subsequent long-term
clopidogrel therapy. Approximately 5 % of these patients
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are likely to be subjected to non-cardiac surgery within a
year following such interventions [25]. In fact, the indi-
cations for clopidogrel therapy extend beyond that of just
patients following coronary stenting to that of other cardiac
and vascular conditions. As such the proportion of patients
on long-term clopidogrel therapy who are subjected to non-
cardiac surgery including orthopaedic procedures may be
even higher. In our study both the CG and NCG were well
matched with respect to age, gender, ASA grade and pre-
operative haemoglobin levels, confirming similarity of the
patient profile between the two groups. The mean age was
over 80 years with high prevalence of ASA grade 3 in both
groups. These findings are similar to that of the wider
National Hip Fracture Database (NHFD), which incorpo-
rates hip fracture patients from the majority of healthcare
institutions within the UK [3]. There were no differences
with respect to the prevalence of any of the individual
comorbidities except that of cardiovascular disease. This
was expectedly higher, with over 90 % of patients in the
CG suffering with it.
While it is assumed that prolonged surgery is associated
with increased intra-operative bleeding, it is also entirely
possible that a tendency for increased intra-operative
bleeding may prolong surgical duration owing to extra
attention and time needed for achieving adequate haemo-
stasis and an optimum operative field. Surgical times were
similar with mean operative duration times of less than an
hour in both groups. We hence speculate that intraoperative
bleeding in the CG was perhaps only marginally higher or at
best similar to that of the NCG and hence unlikely to
account for prolonged surgery. We do, however, acknowl-
edge that the determinants of surgical duration are multi-
factorial including surgical experience and other patient
factors such as habitus and body mass index (BMI). Use of a
cemented prosthesis was more common in the CG as
compared with the NCG, which is further explained by the
higher proportion of Austin–Moore prostheses used in the
NCG. This interestingly implies that a higher proportion of
Table 1 Patient characteristic
and comorbidity data for both
groups
SD standard deviation
* Included in regression
analysis
Patient characteristic CG NCG p-Value
Age (mean ± SD) 82.8 ± 7.3 years 83.2 ± 7.8 years 0.82
Gender (male:female) 1:4.6 1:4.2 0.87
ASA grade, number (%)
ASA 1 – 4 (7.7) 0.085*
ASA 2 16 (32) 11 (21.2)
ASA 3 29 (58) 27 (51.9)
ASA 4 5 (10) 10 (19.2)
ASA 5 – –
Preoperative Hb (mean ± SD) 12.5 ± 1.4 g/dL 12.6 ± 1.2 g/dL 0.72
Comorbidities, number (%)
Diabetes mellitus 5 (10) 5 (9.6) 0.60
Hypertension 21 (42) 22 (42.3) 0.57
Respiratory disease 3 (6) 6 (11.5) 0.26
Renal disease 5 (10) 8 (15.4) 0.30
Thyroid disease 2 (4) 4 (7.7) 0.36
Anaemia 15 (30) 14 (26.9) 0.45
Cardiovascular disease 46 (92) 8 (15.4) \0.0001*
Cancer 5 (10) 3 (5.8) 0.48
Thromboembolic disease 5 (10) 4 (7.7) 0.48
Cerebrovascular disease 8 (16) 6 (11.5) 0.36
Dementia 6 (12) 12 (23.1) 0.11*
Aspirin intake 16 (32) 23 (44.2) 0.14*






22 (44) 10 (19.2) 0.01*
Length of surgery
(mean ± SD)
50.5 ± 11.4 min 55.5 ± 15.9 min 0.072*
LOS (mean ± SD) 17.3 ± 13.3 days 20.5 ± 16.6 days 0.28
Anaesthesia type [number (%)]
General 44 (88) 18 (34.6)
Regional 6 (12) 34 (65.4)
SD standard deviation
* Included in regression analysis
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patients in the NCG were considered to have increased
perioperative risk with poor pre-injury mobility. Cemented
hemiarthroplasties have equivalent outcomes with similar
complication rates compared with hydroxyapatite-coated
uncemented hemiarthroplasties [26–28], and their use in our
study simply reflects supervising surgeon preference.
The mean postoperative haemoglobin levels were sim-
ilar in the two groups. The drop in mean haemoglobin
levels from surgery was 1.66 and 1.49 g/dL in the CG and
NCG, respectively. The changes are modest compared with
that of others evaluating blood loss from hip fracture sur-
gery while on antiplatelet therapy of aspirin or clopidogrel
[29, 30]. These studies, however, attribute extracapsular
fracture patterns as a cause for such increased blood loss.
The exclusion of extracapsular fractures from our study
cohorts may explain the comparatively smaller changes in
haemoglobin levels postoperatively. There was no differ-
ence in transfusion rates between the two groups. The
relative risk estimate of transfusion while on clopidogrel
after adjustment for covariates was not significant at 3.96
(95 % CI 0.40–39.68). Our results are in agreement with
that of the study by Nydick et al. [31], which showed no
difference in transfusion rates between patients continued
on clopidogrel and those who were not during acute trauma
orthopaedic surgery of both upper and lower limbs. Simi-
larly, a presentation given at the annual meeting of the
Orthopaedic Trauma Association in 2008 found no differ-
ence in bleeding complications or transfusion requirement
in a cohort of 498 patients with either clopidogrel, aspirin
or no antiplatelet therapy during hip fracture treatment
[32]. In contrast, previous studies have shown increased
bleeding and transfusion complications while continuing
clopidogrel during cardiac surgery [11]. These findings
should, however, be interpreted in light of the fact that
cardiac surgery is normally conducted with full intraoper-
ative heparinisation for cardiopulmonary bypass, which
will contribute to such complications.
Although not statistically significant, the trends were in
favour of higher symptomatic haematomas while on
perioperative clopidogrel in our study. Chechik et al. [33] in
their matched cohort study demonstrated an increase in
hidden blood loss in patients on clopidogrel or dual anti-
platelet therapy during hip fracture surgery but failed to
report any significant difference in transfusion rates for the
same. Our findings are consistent with this where the higher
incidence of symptomatic haematomas associated with
perioperative clopidogrel continuation may be analogous to
hidden blood loss into third spaces postoperatively.
Infection rates were low in our study with overall inci-
dence of 2.94 %, with one patient from the NCG developing
a deep wound infection necessitating surgical washout. This
accounted for \1 % of the whole study population. Our
results are comparable to those of previous studies dem-
onstrating deep wound infection rates of 1.2–1.8 % in hip
fracture surgery [34–36]. There was no difference in
infection or reoperation rates between the two groups. In
fact, one patient had a reoperation for dislocation, which
may be considered to be unrelated to antiplatelet therapy.
The covariate-adjusted relative risk for overall complication
while continuing clopidogrel was not significant at 0.43
(95 % CI 0.07–2.60) but may suggest a trend towards a
protective effect. Our findings are in conformity with those
of Nydick et al. and Chechik et al. [31, 33], who showed no
difference in wound infection rates between patients con-
tinued on clopidogrel perioperatively and those who were
not during trauma orthopaedic surgery. In contrast, con-
tinuation of clopidogrel as part of dual antiplatelet therapy
during cardiac surgery has been associated with increased
infection rates [10]. As previously mentioned, cardiac sur-
gery is confounded by intraoperative heparinisation, which
may contribute to subsequent complications including
infection. Furthermore, reports of increased infection rates
associated with the use of low-molecular-weight heparin for
thromboprophylaxis after hip fracture surgery further sup-
ports this notion [37].
There was a significantly larger proportion of patients
who underwent general anaesthesia in the CG compared
with the NCG. This may be attributed to the perceived risks
Table 3 Outcome parameters
for both groups
SD standard deviation
Outcome parameter CG NCG p-Value
Postoperative Hb, mean ± SD 10.8 ± 1.5 g/dL 11.1 ± 1.5 g/dL 0.37
Transfusion given, number (%) 4 (8) 2 (3.85) 0.37
Total no. of units 8 5
Mean no. of units 2 ± 0 2.5 ± 0.71 0.16
Time to transfusion 3 ± 1.8 days 3.5 ± 0.7 days
Adjusted risk ratio (95 % CI) 3.96 (0.40–39.68)
Complication—yes/no, number (%) 4 4 1.0
Haematoma 3 1 0.36
Wound infection 1 2 1.0
Reoperation 1 2 1.0
Adjusted risk ratio (95 % CI) 0.43 (0.07–2.60)
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of regional anaesthesia in patients on antiplatelet therapy.
Only six patients underwent regional anaesthesia in the
CG. None of these patients were on dual antiplatelet
therapy. Our study is in keeping with the recommended
guidelines regarding implementation of regional anaes-
thesia in patients on antiplatelet therapy [12]. There were
no anaesthetic-related complications in either group. Use of
regional anaesthesia in hip fracture patients is often pre-
ferred due to the presence of multiple comorbidities and
limited physiological reserve to withstand general anaes-
thesia. However, the absence of any complications in the
use of general anaesthesia in the CG supports the relative
safety of its use. A previous meta-analysis suggested some
advantage in the use of regional anaesthesia in terms of
reducing postoperative confusion but failed to conclude on
any difference with respect to mortality or other outcomes
between the two anaesthetic types [38]. A recent random-
ised prospective study comparing general and regional
anaesthesia in hip fracture patients showed similar findings
of no difference in mortality but increased postoperative
complications and pain with the use of general anaesthesia
[39]. The advantages of early surgery within 48 h are well
established for hip fracture management in terms of
reducing the risk of death [17, 18, 40], while in contrast the
use of regional anaesthesia in hip fracture surgery does not
confer any added benefit in terms of reducing mortality.
Hence, the benefits of its use in hip fracture patients on
concomitant clopidogrel therapy where a delay of[48 h is
required prior to definitive surgical management is out-
weighed by the benefits of reduced mortality risk for
expedited surgery under general anaesthesia.
Our study is limited by its retrospective design and
relatively small sample size. We did, however, identify our
patient samples from a wider institutional audit database of
hip fracture patients with strict exclusion criteria in order to
maintain a homogeneous sample. As a result we excluded
extracapsular fractures, and perhaps their inclusion in a
separate analysis would have allowed us to draw conclu-
sions applicable to the wider population of patients with
different hip fracture patterns.
In conclusion, our data supports the argument for
continuing clopidogrel throughout the perioperative period
of hip hemiarthroplasty surgery in high-risk patients where
the risks of its discontinuation may be associated with
significant morbidity and even an increased risk of mortality
[41]. We observed no increased risk of complications in the
cohort continued on their long-term clopidogrel therapy
perioperatively. Use of general anaesthesia in such patients
can be safely implemented, avoiding the potential problems
of regional anaesthesia related to antiplatelet therapy.
However, we recognise that complex pathophysiological
interactions may be involved in the anaesthetic and peri-
operative management of such elderly and comorbid
patients, and as such an individualised approach in dealing
with perioperative clopidogrel therapy is required. None-
theless, larger prospective comparative studies assessing the
outcomes of hip fracture surgery while on concomitant
clopidogrel therapy are still required to strengthen the evi-
dence for such clinical practice.
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